Lurbinectedin is a promising new drug that has been undergoing clinical trials for the treatment of various types of cancer. According to the sources provided, the results of these trials have been generally positive.

One study published in the Journal of Clinical Oncology [3] evaluated the efficacy and safety of lurbinectedin in patients with advanced solid tumors. The study found that lurbinectedin had antitumor activity and was well-tolerated by patients. Another study [2] focused on the use of lurbinectedin in patients with small cell lung cancer, a particularly aggressive form of the disease. This study found that lurbinectedin showed promising activity in these patients, with a response rate of 35%.

A third source [1] provides information on the patent status of lurbinectedin, which suggests that the drug is still in development and has not yet been approved for use by regulatory agencies.

Overall, while the results of lurbinectedin trials are still preliminary, they suggest that the drug may be a promising new treatment option for certain types of cancer. Further research will be needed to fully evaluate the safety and efficacy of this drug, but the initial findings are encouraging.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469650/
[3] https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e20619